HMN 2025: How Researchers uncover a possible new therapeutic goal for a hard-to-treat type of leukemia

A brand new goal for potential remedies for blast section myeloproliferative neoplasm (BP-MPN), one of the crucial aggressive types of leukemia, has been recognized by a analysis staff on the University of Oxford.

The paper, “Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A,” was revealed in Nature Genetics.

In the research, researchers investigated the position of chromothripsis—a dramatic occasion during which chromosomes shatter and are stitched again collectively in disordered methods—in BP-MPN, a characteristically treatment-resistant sort of leukemia.

The staff, led by the Mead Group on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM), discovered {that a} quarter of sufferers with BP-MPN carried an irregular achieve of genetic materials from chromosome 21, often called chr21amp.

The staff analyzed samples from 64 sufferers with BP-MPN. In some instances, this irregular achieve was attributable to chromothripsis, highlighting the disruptive affect of this phenomenon in cancer genomes.

Crucially, the research confirmed that this chromosome amplification was linked to poorer outcomes in sufferers with BP-MPN, making it a possible biomarker for extra aggressive illness.

Within the amplified area, researchers recognized a single gene, DYRK1A, as constantly overexpressed and extra accessible within the DNA of cancer cells carrying this abnormality.

Further experiments revealed that the BP-MPN leukemia cells are extremely depending on DYRK1A for survival and progress. Blocking DYRK1A—both by genetic knockdown or utilizing chemical inhibitors—considerably impaired the cancer cells in each lab and animal models.

Lead creator Charlotte Brierley stated, “Together, these findings recommend that chr21amp just isn’t solely a marker of poor prognosis in BP-MPN but additionally factors to DYRK1A as a promising druggable goal that arises particularly from chromothripsis-related adjustments within the cancer genome.

This is the primary time that chromothripsis has been linked to a therapeutic vulnerability. Although BP-MPN leukemia is uncommon, these findings might be relevant in different types of cancer.”

Professor Adam Mead, who supervised the work, stated, “This is a pleasant instance of how deep molecular profiling of affected person samples can result in the invention of novel remedy targets in illnesses with an unmet want. As a subsequent step, we’re exploring the opportunity of beginning a scientific trial utilizing already accessible DYRK1A inhibitors.”